Drug fusions and conjugates with extended half life
AssigneeGlaxo Group Limited
InventorsBruce Hamilton, Christopher Herring, Mark Andrew Paulik
Life of this patent
Estimating the term…
Abstract
The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.
Claims10
A pharmaceutical combination which comprises:
- (a) a PYY fusion or PYY conjugate, wherein said PYY fusion or PYY conjugate comprises a PYY peptide and a protein or peptide that comprises a domain antibody (dAb) that extends the half life of the PYY peptide by binding to human serum albumin;
- (b) an exendin-4 fusion or exendin-4 conjugate, wherein said exendin-4 fusion or exendin-4 conjugate comprises an exendin-4 peptide and a protein or peptide that comprises a domain antibody (dAb) that extends half life of the exendin-4 peptide by binding to human serum albumin;
- and
- (c) at least one a pharmaceutically acceptable carrier, excipient or diluent.
Dependencies are inferred from the claim text.